JV-213
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for JV-213, covering 2025-11-10 to 2025-11-10. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas [Phase 1]